Postcardiotomy shock (PCS) is poorly defined in the literature, but is broadly understood to mean circulatory failure after cardiac surgery necessitating mechanical circulatory support and high-dose inotropes. PCS occurs in 0.5% to 1.5% of all cardiac surgeries and is important to better understand because it has an in-hospital mortality rate >50%. 1,2 In the past there were a limited number of ways to support a patient in such profound cardiogenic shock, but today there are multiple mechanical circulatory support devices available. These include extracorporeal membrane oxygenation (ECMO), and several distinct technologies that fall into the category of ventricular assist device (VAD). VADs can be further classified by whether they provide short-term or long-term support, and percutaneous versus open insertion. 2 ECMO has become the most widely used support system for PCS. 3 Relative ease of ECMO cannulation and ability to deploy ECMO quickly in an emergency likely contribute to widespread use. Over the past 2 decades there has been a large increase in use of ECMO for all underlying etiologies, and a fivefold increase in the use of ECMO specifically for PCS. Unfortunately, the increase in use has not been paralleled by improved survival for patients in whom it is used. 3,4 The percentage of PCS patients treated with ECMO who survive to hospital discharge varies on the basis of source, but ranges from approximately 30% to 60%. [4][5][6] Several retrospective analyses have attempted to identify patient-specific characteristics associated with mortality in PCS patients. 3,6,7 A variety of factors have been identified in at least 1 study including age older than 70 years, preoperative renal insufficiency, obesity, female sex, and type of cardiac surgery among others. 1,3,6 In a recent analysis patients in two 5-year time periods (2007( -2012( and 2013